Stocks and Investing
Stocks and Investing
Wed, May 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matt O"Brien Reiterated (TMDX) at Buy with Increased Target to $120 on, May 1st, 2024
Matt O"Brien of Piper Sandler, Reiterated "TransMedics Group, Inc." (TMDX) at Buy with Increased Target from $95 to $120 on, May 1st, 2024.
Matt has made no other calls on TMDX in the last 4 months.
There is 1 other peer that has a rating on TMDX. Out of the 1 peers that are also analyzing TMDX, all agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;
Cecilia Furlong of "Morgan Stanley" Maintained at Hold with Increased Target to $95 on, Wednesday, February 28th, 2024
Contributing Sources